Factor XII

And number two is Amresabart, which you can look at as an upstream targeting of the A2 domain of factor XI.

That is the point at which upstream factors like factor XIIa and its complex which would activate Factor XI, would bind to Factor XI.

So you have two different ways of targeting Factor XI.

And by taking two antibodies forward, it's our way of exploring the science around how best to optimize Factor XI targeting.

The last preclinical sets of studies that we had performed with these antibodies was to look at how they fare in a contact me at thrombosis model in non-human primates using a hemodialysis model.

And in these studies, they show that they do prevent contact me at thrombosis without an increase in bleeding time.

What did this comparison between the two antibodies teach us about the relative contributions of factor XIIa-mediated versus thrombin-mediated factor XI activation?

For our activity assays, what we found was that inhibiting The factor XIIa activation of factor XI occurs for both antibodies.

Yes, thank you.

It's a bit mystical, isn't it? Lots to learn still about Factor XII.

How about you, Alison? Which one's your favorite? I'm horrible at favorites, but I will go with 13.

In addition to doing clinical hematology, I also work in the laboratory.